New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 1, 2013
09:25 EDTDELL, ALKS, LTM, MAT, MCK, NFLX, VVUS, GDOT, CTRP, TSN, MRK, ADNC, ELNOn The Fly: Pre-market Movers
UP AFTER EARNINGS/GUIDANCE: Audience (ADNC), up 30%... Tyson Foods (TSN), up 3.3%... Ctrip.com (CTRP), up 8.5%... Green Dot (GDOT), up 6.5%... ALSO HIGHER: Dell (DELL), up 6% after Reuters says 'go private' deal may happen Monday... VIVUS (VVUS), up 5.7% after study published on weight loss drug improving cardiovascular disease risk factors... Netflix (NFLX), up 3.3% after Morgan Stanley raises price target on shares to $200... DOWN AFTER EARNINGS/GUIDANCE: Merck (MRK), down 2.9%... McKesson (MCK), down 2.1%... Mattel (MAT), down 1.7%... Life Time Fitness (LTM), down 16.4%... ALSO LOWER: Alkermes (ALKS), down 5.9% after Elan (ELN) to sell remaining stake, shares downgraded to Neutral at BofA Merrill Lynch.
News For DELL;ADNC;MRK;TSN;CTRP;GDOT;VVUS;NFLX;MCK;MAT;LTM;ALKS;ELN From The Last 14 Days
Check below for free stories on DELL;ADNC;MRK;TSN;CTRP;GDOT;VVUS;NFLX;MCK;MAT;LTM;ALKS;ELN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
April 14, 2014
18:00 EDTMRKU.S. FDA approves Merck's GRASTEK
Subscribe for More Information
13:19 EDTNFLXNetflix's streaming speeds on Comcast jumped, The Verge reports
Subscribe for More Information
09:36 EDTNFLXActive equity options trading on open
Subscribe for More Information
06:08 EDTMRKMerck volatility elevated into Q1 and outlook
Subscribe for More Information
April 11, 2014
15:44 EDTTSNTyson, Post final contenders to buy Michael Foods, Reuters says
Michael Foods, the egg and dairy products maker that has been put up for sale by Goldman Sachs' (GS) private equity arm, is evaluating binding bids from Tyson (TSN) and Post (POST) and is near a deal to be sold to one of the two for close to $2.5B, according to Reuters, citing people familiar with the matter. Reference Link
10:56 EDTCTRPOptions with increasing implied volatility: CYTK VJET DATA GRPN CTRP
10:29 EDTCTRPRumor: Ctrip.com moves up on renewed takeover chatter
Subscribe for More Information
09:37 EDTNFLXActive equity options trading on open
Subscribe for More Information
07:06 EDTVVUSVIVUS announces avanafil clinical data presentation
Subscribe for More Information
05:22 EDTMRKMerck says Hepatitis C combination therapy shows antiviral activity
Subscribe for More Information
April 10, 2014
17:44 EDTMRKMerck stock could return 20%, Barron's says
Subscribe for More Information
16:00 EDTNFLXOptions Update; April 10, 2014
Subscribe for More Information
12:52 EDTNFLXCarl Icahn says eBay separation 'not if but when'
Subscribe for More Information
10:00 EDTNFLX, ALKSOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:37 EDTMRKActive equity options trading on open
Active equity options trading on open according to Track Data: SIRI RAD AAPL AMZN AA FB TSLA MRK CVX C
09:21 EDTMRKOn The Fly: Pre-market Movers
Subscribe for More Information
08:44 EDTNFLXNetflix upgraded to Buy from Hold at Hudson Square
Subscribe for More Information
08:03 EDTMRKXencor Merck receives milestone payment from Merck for using XmAb antibody
Xencor (XNCR) announced that the company has received a milestone payment from Merck (MRK), through a subsidiary, triggered by the initiation of a Phase 1 clinical trial for an undisclosed biologic drug candidate that uses Xencor's XmAb antibody engineering intellectual property. Under the terms of the agreement signed in June 2013, Xencor granted Merck a non-exclusive license to certain Xencor patents for use in an undisclosed product, as well as an option to license the same intellectual property for future products. Xencor received an upfront payment and continues to receive annual maintenance fees. Xencor is also eligible to receive milestone payments associated with the successful development of Merck product candidates, as well as royalties on sales of any potential products that may result from this agreement.
05:55 EDTALKSAlkermes upgraded to Buy from Neutral at Mizuho
Subscribe for More Information
05:27 EDTMRKMerck announces data from C-WORTHy study
Merck announced additional data from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of a once-daily, all-oral regimen combining MK-5172, an investigational hepatitis C virus, or HCV, NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection, or GT1. In an interim analysis of treatment-na´ve, non-cirrhotic patients administered a 12-week regimen of MK-5172/MK-8742, with and without ribavirin, or RBV, a sustained viral response, or SVR, was observed in 98% of patients administered MK-5172/MK-8742 alone and 94% in those administered MK-5172/MK-8742 plus RBV.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use